

1 **Article title: “Incidence and Outcomes of Pulmonary embolism among hospitalized COVID-19**
2 **patients”**

3

4 **Short running title: Pulmonary embolism and COVID-19**

5 **Authors’ names:**

6 Omaima Ibrahim Badr, M.D,^{1,2} Hassan Alwafi, M.D,³ Wael Aly Elrefaey, MD,² Abdallah Y Naser,
7 PhD,⁴ Mohammed Shabrawishi, M.D,^{2,5}

8

9 **Authors affiliations:**

10 ¹Department of Chest Medicine, Mansoura University, Faculty of medicine, Egypt.

11 ²Department of Pulmonary Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia,

12 ³Department of Clinical Pharmacology and Toxicology, Faculty of Medicine, Umm Al Qura
13 University, Mecca, Saudi Arabia.

14 ⁴Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra
15 University, Amman, Jordan.

16 ⁵Department of Internal Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia.

17

18 **Corresponding author**

19 Dr.Hassan Alwafi

20 Department of Clinical Pharmacology and Toxicology

21 Umm Alqura University, Faculty of Medicine

22 Mecca, Saudi Arabia

23 Post Code 24381

24 T +966555544319

25 Email: hhwafi@uqu.edu.sa

26

27

28 Number of words in abstract: 254

29 Number of words in main body text: 2531

30 Number of tables in main body text: 4

31 Number of references in main body text: 26

32

33

34 **Abstract**

35 **Background:** Patients with COVID-19 may be at high risk for thrombotic complications due to excess
36 inflammatory response and stasis of blood flow. This study aims to assess the incidence of pulmonary
37 embolism among hospitalized patients with COVID-19, risk factors and the impact on survival.

38 **Method:** A retrospective case-control study was conducted at Al-Noor Specialist Hospital in, Saudi
39 Arabia between March 15, 2020, and June 15, 2020. Patients with confirmed COVID-19 diagnosis by
40 a real-time polymerase chain reaction (PCR) and confirmed diagnosis of pulmonary embolism by
41 Computed Tomography pulmonary angiogram (CTPA) formed the case group. Patients with
42 confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR) and without
43 confirmed diagnose of pulmonary embolism formed the control group. Logistic regression analysis
44 was used to identify predictors of pulmonary embolism and its survival.

45 **Results:** A total of 159 patients participated were included in the study, of which 51 were the cases
46 (patients with pulmonary embolism) and 108 patients formed the control group (patients without
47 pulmonary embolism). The incidence of PE among hospitalized was around 32%. Smoking history, low
48 level of oxygen saturation and higher D-dimer values were important risk factors that were associated
49 with a higher risk of developing PE ($p < 0.05$). Higher respiratory rate was associated with higher odds
50 of death, and decrease the possibility of survival among hospitalised patients with PE.

51 **Conclusion:** Pulmonary embolism is common among hospitalized patients with COVID-19. Preventive
52 measures should be considered for hospitalized patients with smoking history, low level of oxygen
53 saturation, high D-dimer values, and high respiratory rate.

54 **Keywords:** COVID-19; Hospitalized; Pulmonary embolism; Survival

55

56

57

58

59

60

61

62

63 **Introduction**

64 The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in
65 Wuhan city, China at the end of 2019 and since then it has spread in more than 190 countries across
66 the world. The total number of confirmed cases as of August 2020 was \approx 20 million, with \approx 700,000
67 confirmed deaths (1). The severity of the disease can range from being asymptomatic, mild or
68 moderate to severe, with multi-organ failure and death (2, 3). Acute respiratory distress syndrome,
69 which is one of the major complications of coronavirus disease of 2019 (COVID-19), is associated
70 with a high mortality rate and is considered the main cause of death (4, 5). Venous and arterial
71 thrombosis is considered one of the most severe consequences of the disease and has poor prognostic
72 outcomes (6, 7). Patients with COVID-19 may be at a high risk of thrombotic complications due to
73 excess inflammatory response, platelet activation, endothelial dysfunction, and stasis of blood flow (8,
74 9). At present, it has been suggested that patients with COVID-19 infection have an increased risk of
75 thrombosis (10). In addition, recent data has suggested that increased levels of the D-dimer test can be
76 a predictor of adverse outcomes such as underlying coagulopathy and thrombotic risk in patients with
77 COVID-19 (11, 12). However, the published data are very limited, with no previous studies on the
78 incidence and risk factors of PE in patients with COVID-19 in the Middle East. Therefore, this study
79 aims to assess the incidence of pulmonary embolism among hospitalized patients with COVID-19,
80 risk factors, and the impact on survival.

81 **METHODS**

82 **Study Design and participants**

83 A retrospective case-control study was conducted at Al-Noor Specialist Hospital in Mecca, Saudi
84 Arabia. The description of the study settings and the hospital has been described previously (1). All
85 patients had a confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR). The
86 PCR samples were obtained through a nasopharyngeal swap. The patients underwent a Computed
87 Tomography pulmonary angiogram (CTPA) for the diagnosis of pulmonary embolism (PE). All
88 patients were admitted between March 15, 2020, and June 15, 2020, and they were followed up for a
89 time to assess the clinical outcome, and the final date of follow-up was August 15, 2020. Patients
90 younger than 15 years old, and patients who were not eligible for CTPA pulmonary angiography,
91 were excluded from the study.

92 **Data Collection and study variables**

93 Data were collected from medical files and electronic records using a unique medical record number
94 (MRN) for each patient. Data included the patient's demographics, clinical symptoms (fever, cough,
95 SOB, nausea, vomiting, diarrhoea, headache, body aches, loss of smell and loss of taste),
96 comorbidities and chest radiograph. These data were collected on admission to the hospital. Clinical
97 signs, including heart rate, respiratory rate and SO₂% on room air, were collected at the time of
98 CTPA. Data regarding risk assessments for thromboembolism including age, smoking, obesity
99 (defined as BMI \geq 30), D-dimer level, the severity of the disease (critical (in ICU) and non-critical
100 (outside ICU)), the time between the admission and the CTPA, the presence of comorbidities, the risk
101 of disseminated intravascular coagulation (DIC), including CBC (WBC, platelets and haemoglobin
102 level), and the coagulation parameters (PT, PTT and INR) were collected in the same day or within 24
103 hours of the Computed Tomography pulmonary angiogram (CTPA). The radiological examinations
104 including the CTPA were reviewed by a senior certified chest radiologist that classified the pulmonary
105 embolism to the main trunk, lobar, segmental and subsegmental; RV strain by CT was defined as a
106 right ventricle to left ventricle size ratio of \geq 0.9. In addition, pulmonary systolic pressure, right
107 ventricular (RV) dysfunction (diagnosed by qualitative and quantitative RV dilation or RV systolic
108 dysfunction), left ventricular (LV) dysfunction (defined as decreased left ventricular systolic function
109 with decreased LV ejection fraction, regional wall motion abnormalities or both), and visualization of
110 thrombus in the right heart or the pulmonary artery were diagnosed through trans-thoracic
111 echocardiography, which was reviewed by an experienced, board-certified echocardiography
112 attending physician.

113 **Case definition**

114 Patients with a confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR) and
115 without a confirmed diagnosis of pulmonary embolism formed the control group.

116 **Control definition**

117 Patients with a confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR) and
118 without a confirmed diagnosis of pulmonary embolism formed the control group.

119 **Outcomes**

120 The outcome predictors of those patients were admission to an intensive care unit, intubation and
121 connection to mechanical ventilation, thrombolytic therapy or catheter-directed thrombolysis, bleeding
122 (minor or major bleeding) as a complication of PE therapy, a prolonged hospital stay (\geq 2 weeks), and
123 mortality.

124 **Statistical Analysis**

125 Descriptive statistics were used to describe patients' demographic characteristics, radiological
126 findings, clinical signs and symptoms, and comorbidities. Continuous data were reported as mean \pm
127 SD for normally distributed data and as median (interquartile range (IQR)) for not normally
128 distributed data, and categorical data were reported as percentages (frequencies). Independent sample
129 t-test/ANOVA was used to compare the mean value for normally distributed continuous variables and
130 The Mann-Whitney U test/Kruskal-Wallis test was used to compare the median value for not normally
131 distributed ones. A Chi-squared test/Fisher test was used as appropriate to compare proportions for
132 categorical variables. Logistic regression analysis was used to identify predictors of pulmonary
133 embolism and its survival. A confidence interval of 95% ($p < 0.05$) was applied to represent the
134 statistical significance of the results, and the level of significance was assigned as 5%. SPSS
135 (Statistical Package for the Social Sciences) version 25.0 software (SPSS Inc.) was used to perform all
136 statistical analysis.

137 **Ethical approval:** This study was approved by the institutional ethics board at the Ministry of Health
138 in Saudi Arabia (No H-02-K-076-0920-386).

139 **Patient and public involvement**

140 It was not appropriate or possible to involve patients or the public in the design, or conduct, or
141 reporting, or dissemination plans of our research.

142 **Results**

143 **Patient's baseline characteristics**

144 A total of 159 patients participated in the study, of which 51 were the cases (patients with pulmonary
145 embolism) and 108 patients formed the control group (patients without pulmonary embolism). The
146 incidence of PE among hospitalized patients was around 32%. The case and control group showed
147 comparable baseline characteristics; there was no statistically significant difference between the two
148 groups in term of the gender distribution, duration of stay at the hospital, disease history, and most of
149 the reported signs and symptoms ($p > 0.05$). For further details on the baseline characteristics, refer to
150 **Table 1** below.

151 **Vital signs and blood test findings**

152 The case and control groups were comparable in terms of their vital sign measurements (respiratory
153 rate, heart rate, oxygen saturation) and various blood test measurements (haematocrit, HGB, WBC,
154 INR, and PTT). However, PT and D-dimer measures were significantly different between the two
155 groups, where the mean PT value was higher in the control group compared to the case group, and the

156 median D-dimer value was higher among the case group compared to the control group. For further
157 details on vital signs and blood test findings, refer to **Table 2**.

158 **Patient's radiological findings**

159 The majority of pulmonary emboli were located in the segmental branch. There was no statistically
160 significant difference between the case and the control groups in terms of the CT parenchymal
161 findings ($p > 0.05$). RT ventricular dysfunction was more common among the case group compared to
162 the control group, whereas the distribution of LT ventricular dysfunction and systolic pulmonary
163 embolism between the two groups was the same (**Table 3**).

164 **Risk factors of pulmonary embolism and its survival.**

165 Using unadjusted logistic regression, we identified that age, smoking history, a higher respiratory rate,
166 and a higher D-dimer value were associated with a higher risk of developing PE ($p < 0.05$). A higher
167 respiratory rate, higher WBC, higher INR value, longer duration between admission and spiral, longer
168 duration of stay at the hospital, requiring ICU admission, duration of stay at the ICU, and requiring
169 intubation were associated with higher odds of death, and a decrease in the possibility of survival
170 among hospitalized patients with PE ($p < 0.05$). On the other hand, a higher HGB value was
171 associated with higher odds of survival ($p < 0.05$).

172 Adjusting for relevant confounding variables such as age, gender, BMI, renal failure, malignancy,
173 haematological diseases, duration between admission and spiral, duration in the ICU, and intubation,
174 we identified that smoking history, a low level of oxygen saturation, and higher D-dimer values were
175 important risk factors that were associated with a higher risk of developing PE ($p < 0.05$). A higher
176 respiratory rate was associated with higher odds of death, and a decrease in the possibility of survival
177 among hospitalized patients with PE. For further details on the findings of the logistic regression
178 analysis, refer to **Table 4**.

179 **Discussion**

180 To the best of our knowledge, this is the first study that investigated the incidence and risk factors of
181 pulmonary embolism among hospitalized patients with COVID-19 in the Middle East. In this case-
182 control study, we investigated the incidence, risk factors and clinical outcomes among hospitalized
183 patients with pulmonary embolism and COVID-19. The key findings of this study are that smoking
184 history, a low level of oxygen saturation, and higher D-dimer values were important risk factors that
185 were associated with a higher risk of developing PE ($p < 0.05$). A higher respiratory rate was associated
186 with higher odds of death and a decrease in the possibility of survival among hospitalized patients with
187 PE. We found that around 32% of hospitalized patients with COVID-19 who underwent CTPA were
188 diagnosed with PE. This finding coincides with previous studies, which reported that about 37.1% of
189 COVID-19 patients were diagnosed with PE (2). Patients with smoking history values were associated

190 with a higher risk of developing PE. Previous reviews reported a higher risk in current smokers than in
191 individuals who have never smoked (3). Smoking may promote VTE via different mechanisms such as
192 a procoagulant state, reduced fibrinolysis, inflammation, and increased blood viscosity (4, 5).

193 In our study, elevated D-dimer was found in all patients with PE and non-PE; an elevated D-dimer
194 was found in other reports on COVID -19 associated with pneumonia. Researchers attributed this
195 elevation to excessive consumption of coagulation factors. Some other studies showed that up to 90%
196 of patients admitted to the hospital for pneumonia had high procoagulant markers, with D-dimer being
197 one of the most common (6). In our study, there is a significant elevation of D-dimer in the PE group
198 compared to the control group, indicating that CTPA is necessary for the exclusion of PE if there is
199 clinical deterioration. This finding coincides with previous studies, which reported that elevated D-
200 dimer levels correlate with the presence of VTE in COVID-19 patients (7, 8). In our study, patients
201 without PE had a median D-dimer level of 3.7, similar to 3.3 observed in patients with Covid-19 in the
202 study by Reich et al. (9).

203 Pharmacological thromboprophylaxis has shown promise in preventing venous thromboembolism
204 (VTE) for high-risk individuals. The incidence of VTE ranges from 5% to 15% and can be effectively
205 reduced by one-half to two-thirds with appropriate thromboprophylaxis (10). In critically ill patients,
206 the incidence of deep vein thrombosis (DVT) ranges from 13% to 31% without thromboprophylaxis
207 (11). However, this risk can be reduced with pharmacological thromboprophylaxis (12). In our study,
208 all patients were on thromboprophylaxis per guidelines during hospitalization. This finding heightened
209 the risk of venous thromboembolism in COVID-19, despite prophylactic anticoagulation.

210 The association between COVID-19 and hypercoagulopathy had been established in the literature.
211 This hypercoagulable state is found to be correlated with the severity of the illness since both the
212 incidence and the coagulation abnormalities are more apparent in severe cases. Furthermore, the
213 presence of coagulation abnormalities such as elevated D-dimer has been linked with both mortality
214 and the need for mechanical ventilation (13). Despite receiving anticoagulation with at least one
215 prophylactic dose, the incidence of VTE was approximately 24% (8). Several mechanisms contributed
216 to the pathogenesis of micro and macro thrombotic complications in COVID-19. These include the
217 systemic activation of coagulation, and, like other viruses (SARS-COV1 and MERS-COV), SARS-
218 COV2 promotes endothelial dysfunction, vascular leak, and pulmonary microthrombi (14-16).

219 The major entry receptors of SARS-CoV-2, the angiotensin converting enzyme 2 (ACE2), are located
220 at the cell surfaces of many organs and regulate renin angiotensin system (RAS). This binding results
221 in dysregulation of RAS and an increase in the pro-inflammatory cytokines ensuing endothelial
222 dysfunction and micro thrombosis (17-19). Autopsy studies of COVID-19 cases have shown that
223 venous thromboembolic events (PE or DVT) are common. Additionally, features of micro thrombosis
224 and endotheliitis were reported not only in the lungs (20, 21) but also in the heart, intestine and

225 kidneys (22). Additional mechanisms were also described as antiphospholipid antibodies (APSA),
226 where recent publications have reported the association of APSA with thrombotic complications
227 observed in COVID-19 patients (23).

228 We did not find significant differences between the PE and non-PE group regarding ICU admission,
229 connection to mechanical ventilation, survival, or duration of hospital stay. However, the mortality in
230 patients with PE was around 25.5%; this finding coincides with previous studies, which reported a
231 mortality rate of about 20% (24). Also, we found no differences between both groups in the other risk
232 factors for PE, in the duration of hospital admission, and in the duration between admission and the
233 time of CTPA between both groups; however, this may be due to up-regulation of procoagulant
234 activity in COVID-19 infection increasing the risk of PE. The coexistence of pneumonia and PE has
235 been known for years, and data from the international cohort RIETE showed that patients with
236 respiratory infections had a higher risk of PE procoagulant activity than patients with other types of
237 infections (25). Patients with coronavirus disease 2019 (COVID-19) pneumonia may be predisposed
238 to thrombotic complications due to excess inflammatory response, endothelial dysfunction, platelet
239 activation, and stasis of blood flow (26). In our study, there was no significant difference between
240 both groups in the duration of hospital admission or the duration between admission and the time of
241 CTPA, suggesting that there are other mechanisms related to COVID-19 that promote the
242 coagulopathy, which should be studied in the future.

243 The results of this study demonstrated a high incidence of pulmonary embolism among hospitalized
244 patients with COVID-19, and this finding should alert health care providers to suspect a diagnosis of
245 PE in COVID-19 patients, especially when clinical signs are associated with significant elevation of
246 D-dimer. Further studies are required to determine the duration of thromboprophylaxis in COVID-19
247 patients.

248 This study has some limitations. First, the number of patients included in the study was small, and the
249 study population only included patients from a single-centre hospital in Saudi Arabia. Second, due to the
250 retrospective nature of the study, we did not have data on the CTPA for all suspected PE patients who were
251 limited by clinical instability or a refusal to do CT with IV contrast. In addition, we were not able to
252 determine if the PE occurred in hospital or before hospital admission.

253 **Conclusions**

254 Our results revealed a high incidence of pulmonary embolism among hospitalized patients with COVID-
255 19. Preventive measures should be considered for hospitalized patients with smoking history, low level of
256 oxygen saturation, high D-dimer values, and a high respiratory rate. More studies are required to evaluate
257 the risk factors and the mechanisms of thrombosis related to COVID-19.

258 **AUTHORS CONTRIBUTIONS**

259 Conceptualization, Hassan Alwafi, Omaira Badr and Wael Elrefaey; Data curation, Omaira Badr
260 and Wael Elrefaey; Formal analysis, Abdallah Y Naser and Hassan Alwafi; Investigation, Omaira
261 Badr and Hassan Alwafi; Methodology, Abdallah Y Naser and Hassan Alwafi; Project administration,
262 Omaira Badr and Hassan Alwafi; Resources, Mohammed Shabrawishi, Omaira Badr, Hassan
263 Alwafi and Wael Elrefaey; Supervision, Omaira Badr and Hassan Alwafi; Validation, Omaira Badr
264 and Hassan Alwafi; Writing – original draft, Mohammed Shabrawishi, Abdallah Y Naser, Omaira
265 Badr and Hassan Alwafi; Writing – review & editing, Mohammed Shabrawishi, Abdallah Y Naser,
266 Omaira Badr, Wael Elrefaey and Hassan Alwafi

267 **CONFLICT OF INTEREST**

268 The authors have stated explicitly that there are no conflicts of interest in connection with this article.

269 **References**

- 270 1. Shabrawishi M, Al-Gethamy MM, Naser AY, Ghazawi MA, Alsharif GF, Obaid EF, et al. Clinical,
271 radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. *PLoS One*.
272 2020;15(8):e0237130-e.
- 273 2. Kaminetzky M, Moore W, Fansiwala K, Babb JS, Kaminetzky D, Horwitz LI, et al. Pulmonary
274 Embolism on CTPA in COVID-19 Patients. *Radiol Cardiothorac Imaging*. 2020;2(4):e200308.
- 275 3. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. *Tob*
276 *Induc Dis*. 2020;18:20-.
- 277 4. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in
278 cigarette smokers. *Thrombosis and haemostasis*. 1998;79(3):549-53.
- 279 5. Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive
280 pulmonary disease. *Proceedings of the American Thoracic Society*. 2005;2(1):71-7.
- 281 6. Alonso-Fernández A, Toledo-Pons N, Cosío BG, Millán A, Calvo N, Ramón L, et al. Prevalence
282 of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A
283 prospective study. *PLoS One*. 2020;15(8):e0238216-e.
- 284 7. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A
285 Pooled Analysis. *Thrombosis and haemostasis*. 2020;120(5):876-8.
- 286 8. Chi G, Lee JJ, Jamil A, Gunnam V, Najafi H, Memar Montazerin S, et al. Venous
287 Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A
288 Systematic Review and Meta-Analysis. *Journal of clinical medicine*. 2020;9(8).
- 289 9. Rech TH, Girardi AM, Gazzana MB. Incidence of pulmonary embolism in patients with COVID-
290 19. *Intensive Care Med*. 2020;46(7):1500-1.
- 291 10. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al. Venous
292 thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the
293 International Medical Prevention Registry on Venous Thromboembolism. *Chest*. 2007;132(3):936-45.
- 294 11. Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical
295 care. *Journal of critical care*. 2002;17(2):95-104.
- 296 12. Laryea J, Champagne B. Venous thromboembolism prophylaxis. *Clin Colon Rectal Surg*.
297 2013;26(3):153-9.
- 298 13. Obi AT, Barnes GD, Napolitano LM, Henke PK, Wakefield TW. A narrative review of venous
299 thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute
300 respiratory syndrome coronavirus 2 infection. *Journal of vascular surgery Venous and lymphatic*
301 *disorders*. 2020.

- 302 14. Potus F, Mai V, Leuret M, Malenfant S, Breton-Gagnon E, Lajoie AC, et al. Novel insights on
303 the pulmonary vascular consequences of COVID-19. *American journal of physiology Lung cellular and*
304 *molecular physiology*. 2020;319(2):L277-L88.
- 305 15. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-
306 19, SARS-CoV-1, MERS-CoV and lessons from the past. *Journal of clinical virology : the official*
307 *publication of the Pan American Society for Clinical Virology*. 2020;127:104362.
- 308 16. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new
309 potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovascular*
310 *research*. 2020;116(6):1097-100.
- 311 17. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19
312 and Its Therapeutic Implications. 2020;127(4):571-87.
- 313 18. Haimei MA. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant
314 and Thrombotic Complications. *Clinical and Applied Thrombosis/Hemostasis*.
315 2020;26:1076029620944497.
- 316 19. Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent
317 implications on the cardiovascular system: From basic science to clinical implications. *J Mol Cell*
318 *Cardiol*. 2020;144:47-53.
- 319 20. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem
320 findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *The Lancet*
321 *Infectious diseases*. 2020;20(10):1135-40.
- 322 21. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and
323 cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.
324 *The Lancet Respiratory medicine*. 2020;8(7):681-6.
- 325 22. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
326 Endothelial cell infection and endotheliitis in COVID-19. *Lancet (London, England)*.
327 2020;395(10234):1417-8.
- 328 23. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid
329 Antibodies in Patients with Covid-19. 2020;382(17):e38.
- 330 24. Xu H, Martin A, Singh A, Narasimhan M, Lau J, Weinberg M, et al. Pulmonary Embolism in
331 Patients Hospitalized With COVID-19 (From a New York Health System). *Am J Cardiol*. 2020;133:148-
332 53.
- 333 25. Frasson S, Gussoni G, Di Micco P, Barba R, Bertoletti L, Nuñez MJ, et al. Infection as cause of
334 immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the
335 RIETE registry. *Journal of Thrombosis and Thrombolysis*. 2016;41(3):404-12.
- 336 26. Bikkdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and
337 Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and
338 Follow-Up: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*.
339 2020;75(23):2950-73.

340 **TABLES LEGENDS**

341 Table 1: Baseline characteristics for the study sample.

342 Table 2: Vital signs and blood tests upon admission.

343 Table 3: Radiological and ECHO findings

344 Table 4: Risk factors of pulmonary embolism and its survival.

345 **TABLES**

Table 1: Baseline characteristics for the study sample.

Demographic variable	Patients with Pulmonary embolism (case) (n= 51)	Patients without Pulmonary embolism (control) (n= 108)	P-Value
Demographics			
Age (years)	56.9 (12.3)	50.9 (15.2)	0.009**
Gender No. (%)			
Male	40 (78.4)	71 (65.7%)	0.139
BMI (kg/m2)	27.7 (5.8)	27.9 (5.8)	0.609
Smoking history			
Smoker	32 (62.7)	29 (26.9)	0.000***
Comorbidities No. (%)			
Diabetes mellitus	24 (47.1)	43 (39.8)	0.388
Hypertension	21 (41.2)	38 (35.2)	0.465
Ischemic heart disease	10 (19.6)	17 (15.7)	0.544
Heart failure	3 (5.9)	6 (5.6)	0.934
Renal failure	0	7 (6.5)	0.060
Malignancy	1 (2.0)	0	0.144
HIV	0	1 (0.9)	0.491
Rheumatologically disease No. (%)			
Rheumatoid arthritis	0	1 (0.9)	0.491
Antiphospholipid syndrome	0	1 (0.9)	0.491
Haematological disease No. (%)			
Sickle cell disease	0	3 (2.8)	0.230
Pulmonary disease (other than pulmonary embolism) No. (%)			

COPD	1 (2.0)	7 (6.5)	0.854
Asthma	1 (2.0)	8 (7.4)	0.719
Tuberculosis	0	2 (1.9)	0.544
IPF	0	1 (0.9)	0.676
Pulmonary hypertension	1 (2.0)	0	0.012*
Sign and symptoms (at presentation to hospital) No. (%)			
Fever	44 (86.3)	80 (74.1)	0.083
Cough	41 (80.4)	85 (78.7)	0.806
Sore throat	20 (39.2)	47 (43.5)	0.608
Dyspnoea	47 (92.2)	98 (90.7)	0.769
Haemoptysis	7 (13.5)	11 (10.2)	0.511
Chest pain	21 (41.2)	26 (24.1)	0.027*
Vomiting	6 (11.8)	28 (25.9)	0.042*
Diarrhea	15 (29.4)	33 (30.6)	0.883
Nausea	21 (41.2)	39 (36.1)	0.539
Loss of smell	4 (7.8)	18 (16.7)	0.133
Loss of taste	4 (7.8)	17 (15.7)	0.170
Headache	22 (43.1)	42 (38.9)	0.610
Bone ache	29 (56.9)	64 (59.3)	0.775
Other No. (%)			
Duration of stay at hospital (median days (IQR))	13.00 (13.00)	15.00 (11.00)	0.983
Duration between admission and spiral (median days)	6.00 (7.00)	5.00 (6.75)	0.953
Outcomes No. (%)			
Survived	38 (74.5)	74 (68.5)	0.440
Died	13 (25.5)	34 (31.5)	0.440
ICU admission (yes)	39 (76.5)	80 (74.1)	0.745

Intubation (yes)	60 (55.6)	32 (62.7)	0.391
Duration of stay at the ICU (median days (IQR))	6.00 (10.00)	7.00 (13.00)	0.524
Medications and management No. (%)			
Mechanical thrombectomy	3 (5.9)	0	0.803
Alteplase	1 (2.0)	0	0.888
Complications of anticoagulant No. (%)			
Minor bleeding	3 (5.9)	0	0.011*

Table 2: Vital signs and blood tests upon admission.

Variable	Patients with Pulmonary embolism (case)	Patients without Pulmonary embolism (control)	P-Value
Respiratory rate	30.5 (5.1)	28.3 (6.3)	0.717
Heart rate	113.9 (13.9)	108.9 (20.5)	0.686
Oxygen saturation	83.7 (8.3)	85.8 (6.5)	0.455
Haematocrit	0.38 (0.07)	0.75 (3.6)	0.204
HGB	127.7 (22.9)	122.0 (24.8)	0.913
WBC (median(IQR))	10.27 (7.06)	9.44 (7.00)	0.188
Platelet count	251.00 (135.00)	256.00 (144.0)	0.971
INR	1.09 (0.17)	1.13 (0.28)	0.938
PTT (median(IQR))	35.30 (8.30)	34.30 (7.40)	0.324
PT	13.3 (1.73)	14.50 (4.70)	0.044*
D-dimer (median(IQR))	13.70 (14.38)	3.70 (4.53)	0.000***

Table 3: Radiological and ECHO findings

Variable	Patients with Pulmonary embolism (case)	Patients without Pulmonary embolism (control)	P-value
Location of pulmonary embolism			
Segmental branch	23 (45.1)	-	-
Main pulmonary trunk	12 (23.5)	-	-
Lobar branch	10 (19.6)	-	-
Sub segmental	6 (11.8)	-	-
CT parenchymal findings			
Bilateral peripheral ground glass	26 (51.0)	50 (46.3)	0.581
Bilateral peripheral ground glass with	23 (45.1)	50 (46.3)	0.887
Unilateral peripheral ground glass	2 (3.9)	8 (7.4)	0.398
ECHO			
<i>RT ventricular dysfunction</i>	25 (49.0)	22 (20.4)	0.000***
<i>LT ventricular dysfunction</i>	4 (7.8)	8 (7.4)	0.575
<i>Systolic pulmonary hypertension</i>	14 (27.5)	24 (22.2)	0.298

Table 4: Risk factors of pulmonary embolism and its survival.

Variable	Risk factors of pulmonary embolism				Factors affecting survival among patients with pulmonary embolism			
	OR (95% CI)	P-value	AOR§ (95% CI)	P-value	OR (95% CI)	P-value	AOR§ (95% CI)	P-value
Demographics and social								
Age (years)	1.03 (1.01 – 1.06)	0.018*	-		0.99 (0.96 – 1.01)	0.230	-	
Gender (female)	0.53 (0.24 – 1.15)	0.107	-		1.19 (0.56 – 2.53)	0.653	-	
Smoking (yes)	4.59 (2.26 – 9.33)	0.000***	3.85 (1.73 – 8.58)	0.001**	1.00 (0.50 – 2.02)	0.991	1.70 (0.46 – 6.27)	0.422
Obesity (BMI> 30 kg/m ²)	1.40 (0.70 – 2.81)	0.337	-		0.87 (0.43 – 1.78)	0.703	-	
Comorbidities								
Diabetes mellitus (yes)	1.34 (0.69 – 2.63)	0.388	1.02 (0.47 – 2.19)	0.969	0.76 (0.38 – 1.52)	0.440	1.14 (0.35 – 3.71)	0.833
Hypertension (yes)	1.29 (0.65 – 2.55)	0.466	1.21 (0.56 – 2.61)	0.623	0.64 (0.32 – 1.28)	0.202	0.65 (0.20 – 2.09)	0.473
Ischemic heart disease (yes)	1.31 (0.55 – 3.10)	0.545	1.05 (0.40 – 2.77)	0.915	0.81 (0.33 – 1.96)	0.638	0.88 (0.20 – 3.87)	0.870
Heart failure (yes)	1.06 (0.26 – 4.43)	0.934	1.22 (0.25 – 6.09)	0.806	0.50 (0.13 – 1.96)	0.322	0.05 (0.00 – 1.24)	0.068
Renal failure (yes)	-		-		-		-	
Malignancy (yes)	-		-		-		-	
Rheumatologically disease (yes)	-		-		-		-	
Haematological disease (yes)	-		-		-		-	
COPD (yes)	0.79 (0.06 – 10.38)	0.855	-		0.90 (0.12 – 7.03)	0.920	-	
Asthma (yes)	0.63 (0.05 – 8.20)	0.720	-		1.17 (0.15 – 9.01)	0.882	-	

Tuberculosis (yes)	-	-	-	-	-	-	-	-
IPF (yes)	-	-	-	-	-	-	-	-
Pulmonary hypertension (yes)	-	-	-	-	-	-	-	-
Vital signs								
Respiratory rate	1.07 (1.00 – 1.15)	0.043*	1.07 (0.99 – 1.15)	0.076	0.91 (0.84 – 0.98)	0.011*	0.82 (0.71 – 0.94)	0.004**
Heart rate	1.02 (1.00 – 1.04)	0.067	1.02 (1.00 – 1.05)	0.061	0.98 (0.96 – 1.00)	0.113	0.97 (0.94 – 1.01)	0.165
Oxygen saturation	0.98 (0.95 – 1.02)	0.279	0.95 (0.90 – 1.00)	0.039*	1.02 (0.99 – 1.06)	0.272	1.05 (0.97 – 1.15)	0.230
Laboratory								
Haematocrit	0.89 (0.48 – 1.64)	0.705	0.74 (0.01 – 65.73)	0.895	-	-	-	-
HGB	1.01 (0.99 – 1.02)	0.438	1.00 (0.98 – 1.02)	0.790	1.03 (1.01 – 1.04)	0.001**	1.01 (0.98 – 1.03)	0.528
WBC	1.02 (0.97 – 1.07)	0.558	1.02 (0.97 – 1.08)	0.407	0.94 (0.89 – 1.00)	0.035*	0.97 (0.88 – 1.06)	0.468
Platelet count	1.00 (1.00 – 1.00)	0.615	1.00 (1.00 – 1.00)	0.972	1.00 (1.00 – 1.00)	0.580	1.00 (1.00 – 1.00)	0.819
PT	0.91 (0.80 – 1.04)	0.174	0.91 (0.80 – 1.04)	0.180	1.04 (0.94 – 1.16)	0.434	1.00 (0.813 – 1.23)	0.985
PTT	1.00 (0.99 – 1.01)	0.642	1.00 (0.99 – 1.01)	0.491	1.00 (1.00 – 1.01)	0.645	1.03 (0.97 – 1.09)	0.310
INR	1.07 (0.26 – 4.34)	0.925	2.31 (0.30 – 17.65)	0.419	0.12 (0.02 – 0.69)	0.018*	0.05 (0.00 – 1.20)	0.065
D dimer	1.17 (1.10 – 1.24)	0.000***	1.21 (1.13 – 1.30)	0.000***	0.99 (0.96 – 1.01)	0.356	0.99 (0.95 – 1.03)	0.685
Other								
Duration between admission and spiral (days)	0.99 (0.92 – 1.07)	0.862	-	-	0.89 (0.83 – 0.96)	0.003**	-	-
Severity of disease (required ICU admission)	1.14 (0.52 – 2.47)	0.745	1.27 (0.46 – 3.48)	0.646	0.04 (0.01 – 0.31)	0.002**	1.79 (0.09 – 36.12)	0.705

Duration of hospital stay (days)	1.00 (0.96 – 1.04)	0.907	1.01 (0.96 – 1.07)	0.695	0.96 (0.93 – 1.00)	0.042*	1.10 (1.00 – 1.21)	0.053
Duration of stay in the ICU (days)	0.98 (0.94 – 1.02)	0.395	-		0.86 (0.82 – 0.91)	0.000***	-	
Intubation (yes)	0.74 (0.38 – 1.47)	0.392	-		0.01 (0.00 – 0.05)	0.000***	-	

§ Adjusted for the following variables: age, gender, BMI, renal failure, malignancy, haematological diseases, duration between admission and spiral, duration in the ICU, and intubation

